Varenicline as a Treatment for Methamphetamine Dependence

NCT ID: NCT01571167

Last Updated: 2013-06-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2012-02-29

Brief Summary

The primary purpose of the study is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on methamphetamine-induced craving and subjective effects in methamphetamine-dependent human volunteers.

Detailed Description

This study is part of an effort to develop treatments for methamphetamine abuse. Varenicline is a drug that changes levels of certain brain chemicals that may also be useful in helping people to stop using methamphetamine. Our goal is to determine the safety and effects of varenicline (1 and 2 mg, daily, vs. a placebo) when it is used before experimental administration of methamphetamine, on a number of physical and psychological measures; specifically blood pressure, heart rate, and how you feel after taking methamphetamine. The secondary purpose is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on the reinforcing effects of methamphetamine by measuring methamphetamine self-administration in methamphetamine-dependent human volunteers.

Conditions

Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).

Varenicline 2 mg

Group Type: ACTIVE_COMPARATOR

Varenicline

Intervention Type: DRUG

For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.

Varenicline 1 mg

Group Type: ACTIVE_COMPARATOR

Varenicline

Intervention Type: DRUG

For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.

Interventions

Placebo

Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).

Intervention Type: DRUG

Varenicline

For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.

Intervention Type: DRUG

Varenicline

For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.

Intervention Type: DRUG

Other Intervention Names

Sugar pill; Chantix; Chantix

Eligibility Criteria

Inclusion Criteria

In order to participate in the study, participants must:

1. Be English-speaking volunteers who are not seeking treatment at the time of the study

2. Be between 18-55 years of age

3. Meet DSM-IV TR criteria for MA dependence

4. Must be cigarette smokers, defined as smoking 10 or more cigarettes per day by self-report

5. Have a self-reported history of using MA by the smoked or IV route and provide at least one MA-positive urine prior to admission

6. Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 105-150 mm Hg systolic and 45-90 mm Hg diastolic; this criterion must be met within 2 days of admission

7. Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) < 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 x the upper limit of normal

8. Have a baseline EKG that demonstrates normal sinus rhythm, normal conduction (including QTc), and no clinically significant arrhythmias

9. Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician or nurse practitioner and the principal investigator.

Exclusion Criteria

Subjects will be excluded if they:

1. Have any previous medically adverse reaction to METH, including loss of consciousness, chest pain, or epileptic seizure

2. Have neurological or psychiatric disorders, as assessed by MINI, such as: episode of major depression within the past 2 years; lifetime history of schizophrenia, other psychotic illness, or bipolar illness; current organic brain disease or dementia assessed by clinical interview; history of or any current psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months and/or current suicidal ideation/plan; history of psychosis occurring in the absence of current METH use

3. Meet DSM-IV criteria for abuse/dependence on alcohol or other drugs, except nicotine or marijuana

4. Have used methamphetamine only by the intravenous route

5. Have evidence of clinically significant heart disease or hypertension, as determined by physician

6. Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease

7. Have HIV and currently symptomatic, have a diagnosis of AIDS, or currently taking antiretroviral medication

8. Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, and throughout the study

9. Have any history of asthma, chronic coughing and wheezing, or other chronic respiratory illnesses

10. Currently use alpha or beta agonists, theophylline, or other sympathomimetics

11. Have made a suicide attempt in the past year

12. Have any other illness, condition, or use of medications, which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of study.

Criteria for Discontinuation Following Initiation:

1. Positive urine drug screen or breath test indicating illicit use of cocaine, MA, alcohol, opiates, or other abused drugs not delivered as part of this protocol

2. Inability to comply with study procedures

3. Meet discontinuation criteria due to exaggerated response to MA, described below

4. Nausea severe enough to require treatment.

Rationale for Subject Selection Criteria:

Participants are required to have used MA by the smoked or IV route to avoid exposing participants to routes of administration that produce more intensive interoceptive effects. The age criteria were selected primarily to avoid enrolling participants with undiagnosed cardiovascular disease. Participants with active HIV disease are excluded to avoid potential exacerbation of their underlying disease; participants with asymptomatic HIV are included because this group is at high risk for MA dependence. Participants with asthma (or who take asthma medications) are excluded due to potential adverse interactions between beta agonist medications and MA.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Richard De La Garza

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Richard De La Garza, II, PhD

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Locations

Michael E. DeBakey Veterans Affairs Medical Center

Houston, Texas, United States

Countries

United States

References

Kalechstein AD, Mahoney JJ 3rd, Verrico CD, De La Garza R 2nd. Short-term, low-dose varenicline administration enhances information processing speed in methamphetamine-dependent users. Neuropharmacology. 2014 Oct;85:493-8. doi: 10.1016/j.neuropharm.2014.05.045. Epub 2014 Jun 12.

Reference Type: DERIVED

PMID: 24930359 (View on PubMed)

Verrico CD, Mahoney JJ 3rd, Thompson-Lake DG, Bennett RS, Newton TF, De La Garza R 2nd. Safety and efficacy of varenicline to reduce positive subjective effects produced by methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2014 Feb;17(2):223-33. doi: 10.1017/S146114571300134X.

Reference Type: DERIVED

PMID: 24393456 (View on PubMed)

Other Identifiers

DPMC

Identifier Type: OTHER

Identifier Source: secondary_id

1R01DA027134-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

H-26875

Identifier Type: -

Identifier Source: org_study_id